secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2021-08-25T23:59:59+00:00
Accession:  0001104659-21-109335
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Replimune eliminates CMO role; Dr. Andrea Pirzkall terminated without cause
---------------------------------------------------------------------------

- All Chief Medical Officer functions now report to President and Chief R&D Officer Dr. Robert Coffin or Chief Development Operations Officer Tanya Lewis.
- Chief Medical Officer role eliminated effective August 25, 2021.
- Dr. Andrea Pirzkall notified of termination without cause on same date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465921109335/0001104659-21-109335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465921109335/tm2125821d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-109335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer